Recently, neoadjuvant immune checkpoint inhibitors (ICI) including programmed cell death‐ligand 1 (PD‐L1) and programmed cell death protein‐1 (PD‐1) inhibitors have proven effective for locally advanced NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.